Latest News

AC Immune says number of families affected by Alzheimer’s could nearly triple by 2050

Stock Markets7 hours ago (Nov 07, 2021 13:21)

© Reuters.

FRANKFURT (Reuters) – Alzheimer’s drug developer AC Immune expects the number of families to be affected by the degenerative disease could nearly triple by 2050 to 150 million, its CEO said in an interview with a German magazine.

The company recently secured a multi-million investment from the main backers of German COVID-19 vaccine developer BioNTech while acquiring a possible Parkinson’s disease vaccine.

AC Immune’s CEO Andrea Pfeifer, in an interview with German business magazine Wirtschaftswoche published in its online edition on Sunday, described Alzheimer’s, a non-curable disease the origin of which is not known, as “a slow pandemic rolling towards the world”. It currently affected 55 million families, she said.

Athos, the holding company of Andreas and Thomas Struengmann – anchor investors in BioNTech – together with financing companies MIG and First Capital Partner jointly hold 12% of AC Immune following a deal concluded a few weeks ago, Pfeifer said. The planned investment was announced in July.

Athos and MIG were involved in founding BioNTech, which with partner Pfizer (NYSE:PFE) developed the Western world’s most widely used COVID-19 vaccine, and they remain the main shareholders.

Pfeifer said having the Struengmann twins on board was a “blessing” for AC Immune.

“If anyone knows how vaccines can be commercialised, then it is the main investors in BioNTech,” she said.

AC Immune is working on several compounds for Alzheimer’s and Parkinson’s diseases, including vaccines.

The company has not yet launched a drug.

Other investors in AC Immune are Dietmar Hopp via his biotech-holding company Dievini with slightly above 20%, as well as institutional and other private investors, Pfeifer said.

AC Immune says number of families affected by Alzheimer’s could nearly triple by 2050

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

You may also like

Leave a reply

Your email address will not be published.

More in Latest News